Headlines about Alkermes PLC (NASDAQ:ALKS) have trended somewhat positive recently, Accern Sentiment reports. The research group scores the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Alkermes PLC earned a daily sentiment score of 0.16 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 59 out of 100, meaning that recent news coverage is somewhat likely to have an effect on the company’s share price in the immediate future.
Here are some of the news headlines that may have effected Accern Sentiment’s analysis:
- Alkermes PLC (ALKS) Given Average Recommendation of “Hold” by Brokerages (americanbankingnews.com)
- United Services Automobile Association Increases Stake in Alkermes Plc (ALKS), Wp Carey Reit (WPC) Stock Price … – BZ Weekly (bzweekly.com)
- Alkermes plc (ALKS) noted a price change of 0.84% and The Ensign Group, Inc. (ENSG) closes with a move of -0.91% – Stocks Gallery (stocksgallery.com)
- Alkermes May Have Lucky Investors Doing A Happy Jig – Seeking Alpha (seekingalpha.com)
- Alkermes Plc – Value Analysis (NASDAQ:ALKS) : June 20, 2017 (finance.yahoo.com)
Several analysts have recently commented on the stock. Cowen and Company restated a “positive” rating and set a $65.00 price objective on shares of Alkermes PLC in a research report on Tuesday, March 21st. ValuEngine upgraded shares of Alkermes PLC from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Leerink Swann downgraded shares of Alkermes PLC from an “outperform” rating to a “market perform” rating and reduced their target price for the stock from $68.00 to $61.00 in a report on Tuesday, June 13th. Credit Suisse Group restated a “buy” rating and issued a $70.00 target price on shares of Alkermes PLC in a report on Wednesday, June 7th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and set a $70.00 price target on shares of Alkermes PLC in a research note on Monday, April 3rd. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Alkermes PLC has a consensus rating of “Hold” and an average price target of $63.10.
Shares of Alkermes PLC (ALKS) traded down 0.36% during midday trading on Friday, hitting $58.47. 992,352 shares of the stock traded hands. The company’s market cap is $8.96 billion. The stock has a 50-day moving average of $58.54 and a 200-day moving average of $57.19. Alkermes PLC has a 52-week low of $39.65 and a 52-week high of $63.40.
Alkermes PLC (NASDAQ:ALKS) last released its earnings results on Thursday, April 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.07. Alkermes PLC had a negative net margin of 25.61% and a negative return on equity of 9.76%. The firm had revenue of $191.80 million during the quarter, compared to analysts’ expectations of $195.79 million. During the same quarter last year, the company posted ($0.16) earnings per share. Alkermes PLC’s revenue for the quarter was up 22.3% on a year-over-year basis. On average, equities analysts predict that Alkermes PLC will post ($0.04) earnings per share for the current fiscal year.
In related news, SVP Michael J. Landine sold 10,000 shares of the stock in a transaction that occurred on Thursday, May 11th. The shares were sold at an average price of $57.01, for a total transaction of $570,100.00. Following the completion of the sale, the senior vice president now owns 172,370 shares of the company’s stock, valued at approximately $9,826,813.70. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Paul J. Mitchell sold 1,500 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $57.49, for a total value of $86,235.00. Following the completion of the transaction, the director now owns 9,500 shares of the company’s stock, valued at approximately $546,155. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 166,570 shares of company stock valued at $9,642,375. Corporate insiders own 5.34% of the company’s stock.
About Alkermes PLC
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.